DeCode Genetics announced today that a mid-stage study of its arterial thrombosis treatment showed positive results in a Phase II study. The company says it expects DG041 will make it possible to block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk. With the development of DG041, DeCode is taking aim at drugs such as Plavix and aspirin, the current market leaders of oral anti-platelet therapy.
- see DeCode's release
DeCode alleges ex-employees stole trade secrets. Report
DeCode IDs tablet problem, suspends pivotal trial. Report
DeCode touts early heart data. Report
DeCode launches genetic trial. Report